DOCSLIB.ORG

Molecular Subtypes of Diffuse Large B-Cell Lymphoma Arise by Distinct Genetic Pathways

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Subtypes of Diffuse Large B-Cell Lymphoma Arise by Distinct Genetic Pathways Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Georg Lenza, George W. Wrightb, N. C. Tolga Emrea, Holger Kohlhammera, Sandeep S. Davea, R. Eric Davisa, Shannon Cartya, Lloyd T. Lama, A. L. Shaffera, Wenming Xiaoc, John Powellc, Andreas Rosenwaldd, German Ottd,e, Hans Konrad Muller-Hermelinkd, Randy D. Gascoynef, Joseph M. Connorsf, Elias Campog, Elaine S. Jaffeh, Jan Delabiei, Erlend B. Smelandj,k, Lisa M. Rimszal, Richard I. Fisherm,n, Dennis D. Weisenburgero, Wing C. Chano, and Louis M. Staudta,q aMetabolism Branch, bBiometric Research Branch, cCenter for Information Technology, and hLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892; dDepartment of Pathology, University of Wu¨rzburg, 97080 Wu¨rzburg, Germany; eDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany; fBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6; gHospital Clinic, University of Barcelona, 08036 Barcelona, Spain; iPathology Clinic and jInstitute for Cancer Research, Rikshospitalet Hospital, Oslo, Norway; kCentre for Cancer Biomedicine, Faculty Division the Norwegian Radium Hospital, N-0310, Oslo, Norway; lDepartment of Pathology, University of Arizona, Tucson, AZ 85724; mSouthwest Oncology Group, 24 Frank Lloyd Wright Drive, Ann Arbor, MI 48106 ; nJames P. Wilmot Cancer Center, University of Rochester, Rochester, NY 14642; and oDepartments of Pathology and Microbiology, University of Nebraska, Omaha, NE 68198 Edited by Ira Pastan, National Cancer Institute, National Institutes of Health, Bethesda, MD, and approved July 7, 2008 (received for review May 2, 2008) Gene-expression profiling has been used to define 3 molecular Recent studies using fluorescence in situ hybridization, con- subtypes of diffuse large B-cell lymphoma (DLBCL), termed germi- ventional comparative genomic hybridization (CGH), or low- nal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, resolution array-based CGH (aCGH) have shown that certain and primary mediastinal B-cell lymphoma (PMBL). To investigate genetic aberrations occur at different frequencies among DLBCL whether these DLBCL subtypes arise by distinct pathogenetic subtypes (4, 9–11). The t(14, 18) translocation involving BCL2 and mechanisms, we analyzed 203 DLBCL biopsy samples by high- amplification of REL was detected in 45% and 16% of GCB resolution, genome-wide copy number analysis coupled with DLBCLs, respectively, but never in ABC DLBCLs (4). Roughly gene-expression profiling. Of 272 recurrent chromosomal aberra- one-quarter of ABC DLBCLs had trisomy 3 or gain/amplification tions that were associated with gene-expression alterations, 30 of chromosome arm 3q, but these abnormalities never were de- were used differentially by the DLBCL subtypes (P < 0.006). An tected in GCB DLBCLs (9, 10). ABC DLBCLs were characterized amplicon on chromosome 19 was detected in 26% of ABC DLBCLs further by frequent gain of 18q and loss of 6q (9, 10). but in only 3% of GCB DLBCLs and PMBLs. A highly up-regulated These relatively low-resolution techniques were unable to gene in this amplicon was SPIB, which encodes an ETS family pinpoint the presumed cancer-relevant target gene in most transcription factor. Knockdown of SPIB by RNA interference was instances. To overcome these limitations, we combined aCGH toxic to ABC DLBCL cell lines but not to GCB DLBCL, PMBL, or using high-density whole-genome microarrays with gene expres- myeloma cell lines, strongly implicating SPIB as an oncogene sion profiling. By this concerted approach, we identifiedchro- involved in the pathogenesis of ABC DLBCL. Deletion of the mosomal aberrations that were significantly more frequent in a INK4a/ARF tumor suppressor locus and trisomy 3 also occurred particular DLBCL subtype than in the others, and some of these aberrations were associated with clinical outcome. This analysis almost exclusively in ABC DLBCLs and was associated with inferior revealed oncogenic pathways that are used differentially by the outcome within this subtype. FOXP1 emerged as a potential DLBCL subtypes, reinforcing the view that they represent oncogene in ABC DLBCL that was up-regulated by trisomy 3 and by pathogenetically distinct diseases. more focal high-level amplifications. In GCB DLBCL, amplification of the oncogenic mir-17–92 microRNA cluster and deletion of the Results and Discussion tumor suppressor PTEN were recurrent, but these events did not Definition of Recurrently Altered Minimal Common Regions (MCRs). occur in ABC DLBCL. Together, these data provide genetic evidence aCGH was performed on 203 DLBCL samples, including 74 that the DLBCL subtypes are distinct diseases that use different ABC DLBCLs, 72 GCB DLBCLs, 31 PMBLs, and 26 unclassi- oncogenic pathways. fied DLBCLs from a previously studied cohort of patients (4). We used oligonucleotide microarrays covering the entire ge- gene-expression profiling ͉ oncogenes ͉ tumor suppressor genes ͉ nome at 5-kb average spacing, allowing us to delineate copy comparative genomic hybridization number changes with great precision. To identify chromosomal aberrations associated with gene-expression changes, we profiled iffuse large B-cell lymphoma (DLBCL) is the most common gene expression in the same samples and developed a statistical Dtype of non-Hodgkin’s lymphoma (1). DLBCL can be cured algorithm termed ‘‘Gene Expression and Dosage Integrator’’ using anthracycline-based chemotherapy regimens in only 40%– (GEDI) to merge the data sets (Fig. 1). For each case, GEDI 50% of patients, suggesting that DLBCL is a heterogeneous divides the aCGH data into intervals with statistically similar diagnostic category (2). Indeed, gene-expression profiling stud- gene dosage, and each interval is classified as an amplification, ies have distinguished 3 molecular subtypes of DLBCL known as ‘‘germinal center B-cell-like’’ (GCB) DLBCL, ‘‘activated B-cell- Author contributions: G.L. and L.M.S. designed research; G.L., N.C.T.E., H.K., S.S.D., R.E.D., like’’ (ABC) DLBCL, and ‘‘primary mediastinal B-cell lym- S.C., L.T.L., and A.L.S. performed research; A.R., G.O., H.K.M.-H., R.D.G., J.M.C., E.C., E.S.J., phoma’’ (PMBL) (3–7). GCB DLBCLs seem to arise from J.D., E.B.S., L.M.R., R.I.F., D.D.W., and W.C.C. contributed new reagents; G.L., G.W.W., W.X., normal germinal center B cells, whereas ABC DLBCLs may J.P., and L.M.S. analyzed data; and G.L., G.W.W., and L.M.S. wrote the paper. arise from postgerminal center B cells that are arrested during The authors declare no conflict of interest. plasmacytic differentiation, and PMBLs may arise from thymic This article is a PNAS Direct Submission. B cells (8). Patients with these DLBCL subtypes have signifi- qTo whom correspondence should be addressed. E-mail: [email protected] cantly different survival rates following chemotherapy (3–6), This article contains supporting information online at www.pnas.org/cgi/content/full/ leading to the current proposal that they represent distinct 0804295105/DCSupplemental. biological disease entities (8). © 2008 by The National Academy of Sciences of the USA 13520–13525 ͉ PNAS ͉ September 9, 2008 ͉ vol. 105 ͉ no. 36 www.pnas.org͞cgi͞doi͞10.1073͞pnas.0804295105 Downloaded by guest on September 26, 2021 Chromosomal position focus attention on more common abnormalities, we limited High resolution Amplification subsequent analysis to the 272 MCRs that occurred in 8 or more array-based Ͼ comparative Gain samples (i.e., 5% of ABC and GCB DLBCL cases) (Table S1). genomic Loss hybridization Double (aCGH) deletion Chromosomal Aberrations Associated with the DLBCL Subtype Dis- Identify tinction. To elucidate oncogenic mechanisms in the DLBCL Gene expression Minimal Common Regions profiling (MCRs) subtypes, we focused our analysis on MCRs that were differen- Correlate gene expression Associate MCRs tially represented among ABC DLBCLs, GCB DLBCLs, and with MCRs with the PMBLs. We further reasoned that such MCRs might be less DLBCL subtype distinction likely to be common copy number polymorphisms present in the (false discovery rate human population (14). { < 5%) MCR Based on a false discovery rate (FDR) of 0.05, we observed 30 MCRs associated with the subtype distinction, far in excess of Fig. 1. Schematic of the Gene Expression and Dosage Integration algorithm chance (Fig. S2 and Table S2). Some of these MCRs probably (see methods). represent similar biology, such as single and double loss of the INK4A/ARF locus, both of which were much more frequent in single-copy gain, single-copy deletion, homozygous deletion, or ABC DLBCLs (Fig. 2). is declared wild type [supporting information (SI) Fig. S1]. Next, Aberrations most characteristic of ABC DLBCL included GEDI defines MCRs of abnormal gene dosage by assembling trisomy 3, deletion of chromosome arm 6q, gain/amplification of segments that affect the same chromosomal region in different a region on chromosome arm 18q, deletion of the INK4a/ARF cases and that belong to the same dosage category (12, 13). tumor suppressor locus on chromosome 9, and gain/amplifica- Finally, the GEDI algorithm determines the degree to which tion of a 9-Mb region on chromosome 19. Aberrations prefer- each gene within an MCR is altered in expression and computes entially used by GCB DLBCLs included amplification of the a statistic, summarizing these correlations across all genes in mir-17–92 microRNA in the MIHG1 locus cluster on chromo- the MCR. some 13, gain/amplification of a 7.6-Mb region on chromosome The GEDI algorithm yielded a total of 1940 MCRs within the 12, deletion of the PTEN tumor suppressor gene on chromosome DLBCL data set, ranging in size from 5 kb, affecting a single 10, and amplification of the REL locus on chromosome 2. The gene, to more than 240 Mb, affecting a whole chromosome. Of most frequent chromosomal lesions in PMBL included amplifi- these MCRs, 719 showed a significant association with gene- cation of a telomeric region of chromosome 9p, monosomy 10, expression alterations, whereas 1221 did not.
Load more

Recommended publications
  • Cyclin D1/Cyclin-Dependent Kinase 4 Interacts with Filamin a and Affects the Migration and Invasion Potential of Breast Cancer Cells
    Published OnlineFirst February 28, 2010; DOI: 10.1158/0008-5472.CAN-08-1108 Tumor and Stem Cell Biology Cancer Research Cyclin D1/Cyclin-Dependent Kinase 4 Interacts with Filamin A and Affects the Migration and Invasion Potential of Breast Cancer Cells Zhijiu Zhong, Wen-Shuz Yeow, Chunhua Zou, Richard Wassell, Chenguang Wang, Richard G. Pestell, Judy N. Quong, and Andrew A. Quong Abstract Cyclin D1 belongs to a family of proteins that regulate progression through the G1-S phase of the cell cycle by binding to cyclin-dependent kinase (cdk)-4 to phosphorylate the retinoblastoma protein and release E2F transcription factors for progression through cell cycle. Several cancers, including breast, colon, and prostate, overexpress the cyclin D1 gene. However, the correlation of cyclin D1 overexpression with E2F target gene regulation or of cdk-dependent cyclin D1 activity with tumor development has not been identified. This suggests that the role of cyclin D1 in oncogenesis may be independent of its function as a cell cycle regulator. One such function is the role of cyclin D1 in cell adhesion and motility. Filamin A (FLNa), a member of the actin-binding filamin protein family, regulates signaling events involved in cell motility and invasion. FLNa has also been associated with a variety of cancers including lung cancer, prostate cancer, melanoma, human bladder cancer, and neuroblastoma. We hypothesized that elevated cyclin D1 facilitates motility in the invasive MDA-MB-231 breast cancer cell line. We show that MDA-MB-231 motility is affected by disturbing cyclin D1 levels or cyclin D1-cdk4/6 kinase activity.
    [Show full text]
  • Molecular Subtypes of Diffuse Large B-Cell Lymphoma Arise by Distinct Genetic Pathways
    Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Georg Lenza, George W. Wrightb, N. C. Tolga Emrea, Holger Kohlhammera, Sandeep S. Davea, R. Eric Davisa, Shannon Cartya, Lloyd T. Lama, A. L. Shaffera, Wenming Xiaoc, John Powellc, Andreas Rosenwaldd, German Ottd,e, Hans Konrad Muller-Hermelinkd, Randy D. Gascoynef, Joseph M. Connorsf, Elias Campog, Elaine S. Jaffeh, Jan Delabiei, Erlend B. Smelandj,k, Lisa M. Rimszal, Richard I. Fisherm,n, Dennis D. Weisenburgero, Wing C. Chano, and Louis M. Staudta,q aMetabolism Branch, bBiometric Research Branch, cCenter for Information Technology, and hLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892; dDepartment of Pathology, University of Wu¨rzburg, 97080 Wu¨rzburg, Germany; eDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany; fBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6; gHospital Clinic, University of Barcelona, 08036 Barcelona, Spain; iPathology Clinic and jInstitute for Cancer Research, Rikshospitalet Hospital, Oslo, Norway; kCentre for Cancer Biomedicine, Faculty Division the Norwegian Radium Hospital, N-0310, Oslo, Norway; lDepartment of Pathology, University of Arizona, Tucson, AZ 85724; mSouthwest Oncology Group, 24 Frank Lloyd Wright Drive, Ann Arbor, MI 48106 ; nJames P. Wilmot Cancer Center, University of Rochester, Rochester, NY 14642; and oDepartments of Pathology and Microbiology, University of Nebraska, Omaha, NE 68198 Edited by Ira
    [Show full text]
  • Early Growth Response 1 Regulates Hematopoietic Support and Proliferation in Human Primary Bone Marrow Stromal Cells
    Hematopoiesis SUPPLEMENTARY APPENDIX Early growth response 1 regulates hematopoietic support and proliferation in human primary bone marrow stromal cells Hongzhe Li, 1,2 Hooi-Ching Lim, 1,2 Dimitra Zacharaki, 1,2 Xiaojie Xian, 2,3 Keane J.G. Kenswil, 4 Sandro Bräunig, 1,2 Marc H.G.P. Raaijmakers, 4 Niels-Bjarne Woods, 2,3 Jenny Hansson, 1,2 and Stefan Scheding 1,2,5 1Division of Molecular Hematology, Department of Laboratory Medicine, Lund University, Lund, Sweden; 2Lund Stem Cell Center, Depart - ment of Laboratory Medicine, Lund University, Lund, Sweden; 3Division of Molecular Medicine and Gene Therapy, Department of Labora - tory Medicine, Lund University, Lund, Sweden; 4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands and 5Department of Hematology, Skåne University Hospital Lund, Skåne, Sweden ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2019.216648 Received: January 14, 2019. Accepted: July 19, 2019. Pre-published: August 1, 2019. Correspondence: STEFAN SCHEDING - [email protected] Li et al.: Supplemental data 1. Supplemental Materials and Methods BM-MNC isolation Bone marrow mononuclear cells (BM-MNC) from BM aspiration samples were isolated by density gradient centrifugation (LSM 1077 Lymphocyte, PAA, Pasching, Austria) either with or without prior incubation with RosetteSep Human Mesenchymal Stem Cell Enrichment Cocktail (STEMCELL Technologies, Vancouver, Canada) for lineage depletion (CD3, CD14, CD19, CD38, CD66b, glycophorin A). BM-MNCs from fetal long bones and adult hip bones were isolated as reported previously 1 by gently crushing bones (femora, tibiae, fibulae, humeri, radii and ulna) in PBS+0.5% FCS subsequent passing of the cell suspension through a 40-µm filter.
    [Show full text]
  • Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
    Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades.
    [Show full text]
  • SUPPLEMENTARY DATA Supplementary Table 1. Top Ten
    SUPPLEMENTARY DATA Supplementary Table 1. Top ten most highly expressed protein-coding genes in the EndoC-βH1 cell line. Expression levels provided for non-mitochondrial genes in EndoC-βH1 and the corresponding expression levels in sorted primary human β-cells (1). Ensembl gene ID Gene Name EndoC-βH1 [RPKM] Primary β cells [RPKM] ENSG00000254647.2 INS 8012.452 166347.111 ENSG00000087086.9 FTL 3090.7454 2066.464 ENSG00000100604.8 CHGA 2853.107 1113.162 ENSG00000099194.5 SCD 1411.631 238.714 ENSG00000118271.5 TTR 1312.8928 1488.996 ENSG00000184009.5 ACTG1 1108.0277 839.681 ENSG00000124172.5 ATP5E 863.42334 254.779 ENSG00000156508.13 EEF1A1 831.17316 637.281 ENSG00000112972.10 HMGCS1 719.7504 22.104 ENSG00000167552.9 TUBA1A 689.1415 511.699 ©2016 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-0361/-/DC1 SUPPLEMENTARY DATA Supplementary Table 2. List of genes selected for inclusion in the primary screen. Expression levels in EndoC-βH1 and sorted primary human β-cells are shown for all genes targeted for silencing in the primary screen, ordered by locus association (1). For gene selection, the following criteria were applied: we first considered (1) all protein-coding genes within 1 Mb of a type 2 diabetes association signal that (2) had non-zero expression (RPKM > 0) in both EndoC-βH1 and primary human β-cells. Previous studies have shown cis-eQTLs to form a relatively tight, symmetrical distribution around the target-gene transcription start site, and a 1 Mb cut-off is thus likely to capture most effector transcripts subject to cis regulation (2-5).
    [Show full text]
  • SEC22A CRISPR/Cas9 KO Plasmid (M): Sc-435547
    SANTA CRUZ BIOTECHNOLOGY, INC. SEC22A CRISPR/Cas9 KO Plasmid (m): sc-435547 BACKGROUND APPLICATIONS The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and SEC22A CRISPR/Cas9 KO Plasmid (m) is recommended for the disruption of CRISPR-associated protein (Cas9) system is an adaptive immune response gene expression in mouse cells. defense mechanism used by archea and bacteria for the degradation of foreign genetic material (4,6). This mechanism can be repurposed for other 20 nt non-coding RNA sequence: guides Cas9 functions, including genomic engineering for mammalian systems, such as to a specific target location in the genomic DNA gene knockout (KO) (1,2,3,5). CRISPR/Cas9 KO Plasmid products enable the U6 promoter: drives gRNA scaffold: helps Cas9 identification and cleavage of specific genes by utilizing guide RNA (gRNA) expression of gRNA bind to target DNA sequences derived from the Genome-scale CRISPR Knock-Out (GeCKO) v2 library developed in the Zhang Laboratory at the Broad Institute (3,5). Termination signal Green Fluorescent Protein: to visually REFERENCES verify transfection CRISPR/Cas9 Knockout Plasmid CBh (chicken β-Actin 1. Cong, L., et al. 2013. Multiplex genome engineering using CRISPR/Cas hybrid) promoter: drives expression of Cas9 systems. Science 339: 819-823. 2A peptide: allows production of both Cas9 and GFP from the 2. Mali, P., et al. 2013. RNA-guided human genome engineering via Cas9. same CBh promoter Science 339: 823-826. Nuclear localization signal 3. Ran, F.A., et al. 2013. Genome engineering using the CRISPR-Cas9 system. Nuclear localization signal SpCas9 ribonuclease Nat. Protoc. 8: 2281-2308.
    [Show full text]
  • Tumour-Stroma Signalling in Cancer Cell Motility and Metastasis
    Tumour-Stroma Signalling in Cancer Cell Motility and Metastasis by Valbona Luga A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy, Department of Molecular Genetics, University of Toronto © Copyright by Valbona Luga, 2013 Tumour-Stroma Signalling in Cancer Cell Motility and Metastasis Valbona Luga Doctor of Philosophy Department of Molecular Genetics University of Toronto 2013 Abstract The tumour-associated stroma, consisting of fibroblasts, inflammatory cells, vasculature and extracellular matrix proteins, plays a critical role in tumour growth, but how it regulates cancer cell migration and metastasis is poorly understood. The Wnt-planar cell polarity (PCP) pathway regulates convergent extension movements in vertebrate development. However, it is unclear whether this pathway also functions in cancer cell migration. In addition, the factors that mobilize long-range signalling of Wnt morphogens, which are tightly associated with the plasma membrane, have yet to be completely characterized. Here, I show that fibroblasts secrete membrane microvesicles of endocytic origin, termed exosomes, which promote tumour cell protrusive activity, motility and metastasis via the exosome component Cd81. In addition, I demonstrate that fibroblast exosomes activate autocrine Wnt-PCP signalling in breast cancer cells as detected by the association of Wnt with Fzd receptors and the asymmetric distribution of Fzd-Dvl and Vangl-Pk complexes in exosome-stimulated cancer cell protrusive structures. Moreover, I show that Pk expression in breast cancer cells is essential for fibroblast-stimulated cancer cell metastasis. Lastly, I reveal that trafficking in cancer cells promotes tethering of autocrine Wnt11 to fibroblast exosomes. These studies further our understanding of the role of ii the tumour-associated stroma in cancer metastasis and bring us closer to a more targeted approach for the treatment of cancer spread.
    [Show full text]
  • Downloaded from Ftp://Ftp.Uniprot.Org/ on July 3, 2019) Using Maxquant (V1.6.10.43) Search Algorithm
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.17.385096; this version posted November 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. The proteomic landscape of resting and activated CD4+ T cells reveal insights into cell differentiation and function Yashwanth Subbannayya1, Markus Haug1, Sneha M. Pinto1, Varshasnata Mohanty2, Hany Zakaria Meås1, Trude Helen Flo1, T.S. Keshava Prasad2 and Richard K. Kandasamy1,* 1Centre of Molecular Inflammation Research (CEMIR), and Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, N-7491 Trondheim, Norway 2Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore, India *Correspondence to: Professor Richard Kumaran Kandasamy Norwegian University of Science and Technology (NTNU) Centre of Molecular Inflammation Research (CEMIR) PO Box 8905 MTFS Trondheim 7491 Norway E-mail: [email protected] (Kandasamy R K) Tel.: +47-7282-4511 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.17.385096; this version posted November 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Abstract CD4+ T cells (T helper cells) are cytokine-producing adaptive immune cells that activate or regulate the responses of various immune cells.
    [Show full text]
  • Cell Culture-Based Profiling Across Mammals Reveals DNA Repair And
    1 Cell culture-based profiling across mammals reveals 2 DNA repair and metabolism as determinants of 3 species longevity 4 5 Siming Ma1, Akhil Upneja1, Andrzej Galecki2,3, Yi-Miau Tsai2, Charles F. Burant4, Sasha 6 Raskind4, Quanwei Zhang5, Zhengdong D. Zhang5, Andrei Seluanov6, Vera Gorbunova6, 7 Clary B. Clish7, Richard A. Miller2, Vadim N. Gladyshev1* 8 9 1 Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard 10 Medical School, Boston, MA, 02115, USA 11 2 Department of Pathology and Geriatrics Center, University of Michigan Medical School, 12 Ann Arbor, MI 48109, USA 13 3 Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, 14 MI 48109, USA 15 4 Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 16 48109, USA 17 5 Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10128, USA 18 6 Department of Biology, University of Rochester, Rochester, NY 14627, USA 19 7 Broad Institute, Cambridge, MA 02142, US 20 21 * corresponding author: Vadim N. Gladyshev ([email protected]) 22 ABSTRACT 23 Mammalian lifespan differs by >100-fold, but the mechanisms associated with such 24 longevity differences are not understood. Here, we conducted a study on primary skin 25 fibroblasts isolated from 16 species of mammals and maintained under identical cell culture 26 conditions. We developed a pipeline for obtaining species-specific ortholog sequences, 27 profiled gene expression by RNA-seq and small molecules by metabolite profiling, and 28 identified genes and metabolites correlating with species longevity. Cells from longer-lived 29 species up-regulated genes involved in DNA repair and glucose metabolism, down-regulated 30 proteolysis and protein transport, and showed high levels of amino acids but low levels of 31 lysophosphatidylcholine and lysophosphatidylethanolamine.
    [Show full text]
  • COMPARATIVE GENOME-WIDE DNA METHYLATION ANALYSIS in MYOCARDIAL TISSUE from DONORS with and WITHOUT DOWN SYNDROME Romina B. Ceja
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.15.203075; this version posted July 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. COMPARATIVE GENOME-WIDE DNA METHYLATION ANALYSIS IN MYOCARDIAL TISSUE FROM DONORS WITH AND WITHOUT DOWN SYNDROME Romina B. Cejasa, d, Jie Wangb, d, Rachael Hageman-Blairc, Song Liub and Javier G. Blancoa, e Authors’ affiliation: a Department of Pharmaceutical sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, New York, United States of America b Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America c Department of Biostatistics, School of Public Health and Health Professions, State University of New York at Buffalo, Buffalo, New York, United States of America d Both authors contributed equally to this work. e Corresponding author. [email protected]. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, 470 Pharmacy Building, Buffalo, NY 14214 – 8033, United States of America bioRxiv preprint doi: https://doi.org/10.1101/2020.07.15.203075; this version posted July 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
    [Show full text]
  • The Changing Chromatome As a Driver of Disease: a Panoramic View from Different Methodologies
    The changing chromatome as a driver of disease: A panoramic view from different methodologies Isabel Espejo1, Luciano Di Croce,1,2,3 and Sergi Aranda1 1. Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain 2. Universitat Pompeu Fabra (UPF), Barcelona, Spain 3. ICREA, Pg. Lluis Companys 23, Barcelona 08010, Spain *Corresponding authors: Luciano Di Croce ([email protected]) Sergi Aranda ([email protected]) 1 GRAPHICAL ABSTRACT Chromatin-bound proteins regulate gene expression, replicate and repair DNA, and transmit epigenetic information. Several human diseases are highly influenced by alterations in the chromatin- bound proteome. Thus, biochemical approaches for the systematic characterization of the chromatome could contribute to identifying new regulators of cellular functionality, including those that are relevant to human disorders. 2 SUMMARY Chromatin-bound proteins underlie several fundamental cellular functions, such as control of gene expression and the faithful transmission of genetic and epigenetic information. Components of the chromatin proteome (the “chromatome”) are essential in human life, and mutations in chromatin-bound proteins are frequently drivers of human diseases, such as cancer. Proteomic characterization of chromatin and de novo identification of chromatin interactors could thus reveal important and perhaps unexpected players implicated in human physiology and disease. Recently, intensive research efforts have focused on developing strategies to characterize the chromatome composition. In this review, we provide an overview of the dynamic composition of the chromatome, highlight the importance of its alterations as a driving force in human disease (and particularly in cancer), and discuss the different approaches to systematically characterize the chromatin-bound proteome in a global manner.
    [Show full text]
  • Content Based Search in Gene Expression Databases and a Meta-Analysis of Host Responses to Infection
    Content Based Search in Gene Expression Databases and a Meta-analysis of Host Responses to Infection A Thesis Submitted to the Faculty of Drexel University by Francis X. Bell in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2015 c Copyright 2015 Francis X. Bell. All Rights Reserved. ii Acknowledgments I would like to acknowledge and thank my advisor, Dr. Ahmet Sacan. Without his advice, support, and patience I would not have been able to accomplish all that I have. I would also like to thank my committee members and the Biomed Faculty that have guided me. I would like to give a special thanks for the members of the bioinformatics lab, in particular the members of the Sacan lab: Rehman Qureshi, Daisy Heng Yang, April Chunyu Zhao, and Yiqian Zhou. Thank you for creating a pleasant and friendly environment in the lab. I give the members of my family my sincerest gratitude for all that they have done for me. I cannot begin to repay my parents for their sacrifices. I am eternally grateful for everything they have done. The support of my sisters and their encouragement gave me the strength to persevere to the end. iii Table of Contents LIST OF TABLES.......................................................................... vii LIST OF FIGURES ........................................................................ xiv ABSTRACT ................................................................................ xvii 1. A BRIEF INTRODUCTION TO GENE EXPRESSION............................. 1 1.1 Central Dogma of Molecular Biology........................................... 1 1.1.1 Basic Transfers .......................................................... 1 1.1.2 Uncommon Transfers ................................................... 3 1.2 Gene Expression ................................................................. 4 1.2.1 Estimating Gene Expression ............................................ 4 1.2.2 DNA Microarrays ......................................................
    [Show full text]